Glimisave M1 Forte Tablet PR contains a combination of Glimepiride (1mg) and Metformin (1000mg), formulated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and enhancing peripheral glucose uptake and utilization, contributing to improved insulin sensitivity. This dual-action mechanism addresses both insulin deficiency and insulin resistance, making Glimisave M1 Forte effective in controlling blood glucose levels in patients inadequately managed by diet and exercise alone. The prolonged-release (PR) formulation ensures a steady release of active ingredients, promoting better glycemic stability and reducing the risk of hypoglycemia. Glimisave M1 Forte should be used as part of a comprehensive diabetes management plan, including diet, exercise, and regular monitoring of blood glucose levels. It is contraindicated in patients with severe renal or hepatic impairment, metabolic acidosis, or hypersensitivity to its components. Common side effects may include gastrointestinal disturbances and hypoglycemia. Healthcare professionals should tailor therapy based on individual patient needs and monitor for efficacy and adverse reactions.

Dosage & How to Use